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Abstract
Objectives: In February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged $65
years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding on a
2010 recommendation for adults .65 that was limited to those with close contact with infants. We evaluated clinical and
economic outcomes of adding Tdap booster of adults aged $65 to ‘‘baseline’’ practice [full-strength DTaP administered
from 2 months to 4–6 years, and one dose of Tdap at 11–64 years replacing decennial Td booster], using a dynamic model.
Methods: We constructed a population-level disease transmission model to evaluate the cost-effectiveness of
supplementing baseline practice by vaccinating 10% of eligible adults aged $65 with Tdap replacing the decennial Td
booster. US population effects, including indirect benefits accrued by unvaccinated persons, were estimated during a 1-year
period after disease incidence reached a new steady state, with consequences of deaths and long-term pertussis sequelae
projected over remaining lifetimes. Model outputs include: cases by severity, encephalopathy, deaths, costs (of vaccination
and pertussis care) and quality-adjusted life-years (QALYs) associated with each strategy. Results in terms of incremental
cost/QALY gained are presented from payer and societal perspectives. Sensitivity analyses vary key parameters within
plausible ranges.
Results: For the US population, the intervention is expected to prevent .97,000 cases (.4,000 severe and .5,000 among
infants) of pertussis annually at steady state. Additional vaccination costs are $4.7 million. Net cost savings, including
vaccination costs, are $47.7 million (societal perspective) and $44.8 million (payer perspective). From both perspectives, the
intervention strategy is dominant (less costly, and more effective by .3,000 QALYs) versus baseline. Results are robust to
sensitivity analyses and alternative scenarios.
Conclusions: Immunization of eligible adults aged $65, consistent with the current ACIP recommendation, is cost saving
from both payer and societal perspectives.
Citation: McGarry LJ, Krishnarajah G, Hill G, Masseria C, Skornicki M, et al. (2014) Cost-Effectiveness of Tdap Vaccination of Adults Aged $65 Years in the
Prevention of Pertussis in the US: A Dynamic Model of Disease Transmission. PLoS ONE 9(1): e72723. doi:10.1371/journal.pone.0072723
Editor: Harry Zhang, Old Dominion University, United States of America
Received November 30, 2012; Accepted July 12, 2013; Published January 9, 2014
Copyright:  2014 McGarry et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: GH, LJM, NP, MS, MCW (OptumInsight) received funding from GlaxoSmithKline Group of Companies to complete the disclosed research. The GSK
employees listed as coauthors (BA, GK, JR and CM) participated in study design, data collection and analysis, decision to publish, and preparation of the
manuscript.
Competing Interests: The authors have the following interests: GH, LJM, NP, MS, MCW (OptumInsight) received funding from GlaxoSmithKline Group of
Companies to complete the disclosed research and to develop and publish this present manuscript. SIP and MCW have received consulting fees from
GlaxoSmithKline Group of Companies. SIP has an advisory board membership with GlaxoSmithKline group of companies and Sanofi. BA, GK, JR and CM are
existing or previous employees of GlaxoSmithKline Group of Companies. LJM, GH, MS, NP and MCW are employed by OptumInsight. There are no patents,
products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: mcgarry.nagar@gmail.com
Introduction
The full-strength diphtheria-tetanus-acellular pertussis vaccine,
DTaP, was first approved in the US in 1991 for the 4
th and 5
th
doses in the 5-dose diphtheria, tetanus and pertussis series. The
vaccine received approval for all 5 doses in 1997 [1]. The Advisory
Committee on Immunization Practices (ACIP) recommends that
children receive 5 doses of DTaP, at ages 2, 4, 6, 15–18 months,
and 4–6 years. The tetanus-diphtheria vaccine (Td) is given to
adolescents and adults as a booster every 10 years, or after an
exposure to tetanus. As of 2005, ACIP recommends that
adolescents 11–18 years (preferably at age 11 or 12) and adults
19 through 64 years receive a single dose of reduced-antigen
content combined tetanus, diphtheria, and pertussis (Tdap)
vaccine, which also protects against pertussis, as a one-time
replacement for a Td decennial booster [2]. In 2010, ACIP
recommended the expanded use of Tdap, advising that children
aged 7 through 10 years not previously fully vaccinated against
pertussis receive a single dose of Tdap, and that adults $65 years
who have close contact with an infant receive a single dose of
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e72723Tdap if they have not previously received the booster [3]. Despite
recommendations, Tdap coverage remained incomplete in 2011,
at 78.2% for the adolescent booster and 8.2% for the decennial
booster among adults aged ,65.years [4] In February 2012, ACIP
extended the recommendation of Tdap boosting to all adults
(including those aged $65 years) without regard to interval since
last tetanus or diphtheria toxoid-containing vaccine [5].
After the introduction of adult and adolescent Tdap vaccination
in 2005, pertussis incidence decreased from 2004 levels. However,
since 2007, incidence has been increasing and reached its most
recent peak in 2010 [6]. Pertussis incidence continues to be higher
than in the 1990s, and outbreaks have occurred, most recently in
California and Washington State [7,8]. It is unclear whether this
recent increase in incidence reflects changes in epidemiology,
perhaps due to faster than expected waning of the acellular
pertussis vaccine [9], or to changes in disease reporting. Although
pertussis is nationally notifiable, many cases are believed to go
unrecognized and/or unreported [10], so the true incidence of
disease is uncertain.
Vaccines such as Tdap are unusual among health-care
interventions in that their benefits may accrue both to those
receiving the vaccination and others who are not vaccine-
protected. This is most apparent when vaccination leads to
disease eradication such as was the case for smallpox, or when a
once common and devastating disease such as polio is controlled
through an ongoing mass vaccination program [11]. Although the
incidence of pertussis is reduced from the pre-vaccine levels,
outbreaks still occur among unprotected and partially protected
populations, including infants aged less than 6 months, among
whom the death rate is higher than among other age groups
[12,13]. Because these vulnerable populations cannot be directly
protected through vaccination, they rely on indirect protection
from vaccination in other age groups with which they come into
contact (‘‘cocooning’’).
Studies have provided evidence that administering a pertussis
booster in previously-vaccinated populations is cost-effective [14–
16] and that cocooning by vaccinating close contacts of infants is
also a cost-effective way to prevent adverse outcomes in infants
[17]. The current analysis assesses the impact of the 2010 and
2012 decisions to add Tdap vaccination in adults aged $65 years
to the baseline practice prior to 2010. We used a dynamic
transmission model to capture both direct effects of vaccination
among those vaccinated as well as indirect effects of vaccination in
the larger population due to reductions in circulating pertussis.
Direct effects of the $65 vaccination program versus baseline
practice have been documented in a prior study [18] that
considered only vaccine efficacy among vaccinated persons.The
current study was designed to examine both the direct and
hypothetical indirect effects of vaccination based on assumptions
regarding population mixing and disease transmission. We present
results from both a societal and a payer perspective.
Methods
This study used a population-level disease-transmission model
programmed in Microsoft Excel using Visual Basic for Applica-
tions (VBA) to assess public health and cost implications of two
alternative vaccination strategies. (1) The baseline vaccination
strategy is the vaccination practice prior to the updated 2010
ACIP recommendations, of administering DTaP from age 2
months to 4–6 years, and one dose of Tdap once to individuals
11–64 years of age in place of the decennial Td booster. (2) The
intervention strategy is Tdap vaccination of adults aged 65
years in addition to the baseline vaccination strategy, consistent
with the 2010 and 2012 recommendations.
We estimated the effects of the intervention strategy during a
single 1-year season, with consequences of events occurring during
this year projected over the lifetimes of individuals who die or
suffer long-term sequelae. The analytic horizon was selected to
reflect the seasonal nature of pertussis. We assumed that each of
the vaccination strategies had been fully implemented and that
disease incidence rates had reached equilibrium by the study year
such that, with no change in intervention, each year thereafter
could be assumed to have the same incidence.
Epidemiologic model
The epidemiologic analysis was conducted using a dynamic
transmission model based on a Tdap cost-effectiveness model
developed by the University of Groningen (Netherlands) [14],
composed of 8 compartments representing mutually exclusive
health states. The model is age-structured with compartments
repeated for each month of age below 1 year and 1-year age
groups from 1 to 99 years old (Figure 1).
Two types of infection were modeled: primary (I1) and recidive
(I2). Primary infection is defined as the first infection with pertussis
among individuals who have not previously been vaccinated or
infected; recidive is infection with pertussis among those previously
vaccinated or infected but no longer immune. Time spent in each
infected compartment corresponds to the ‘‘infectious’’ period,
during which transmission may occur, and differs by infection
type.
Infants may begin the model in the ‘‘M’’ compartment, where
they are protected by maternal antibodies, or in the susceptible
‘‘S1’’ compartment. When maternal immunity wanes, those
initially protected become susceptible to primary pertussis
infection. Individuals of all ages in S1 can acquire infection from
contact with an infectious person, and move to primary infection.
When patients recover from primary infection, they initially have
immunity against pertussis. As this immunity wanes, they become
susceptible (‘‘S2’’) to a recidive infection (‘‘I2’’).The waning from
immunity to susceptibility follows the same pathway for recidive as
for primary infection.
Individuals effectively vaccinated against pertussis are protected
by vaccination (‘‘VIm1’’). Upon waning, they become susceptible
to recidive infection in the same way as those recovering from
infection. Vaccination is assumed to provide no additional
protection to infected individuals beyond the immunity already
conferred by the infection. Each compartment is subdivided to
track whether individuals have received Tdap vaccination.
Individuals previously vaccinated with Tdap are indicated by
‘‘B’’ (boosted), and those not previously vaccinated with Tdap are
labeled ‘‘NB’’. Consistent with current recommendations, indi-
viduals may receive Tdap only once, although individuals
previously boosted may no longer be protected.
Transmission rates within the population depend on the ages of
susceptible and infected individuals. Both the transmission rates
and duration of infectiousness differ depending on the type of
infections, with recidive infection (I2) assumed to be 70% as
transmissible as a primary infection [14]. Transmission rates were
estimated using a calibration process, detailed in the Appendix, in
which we used assumed rates of contact among the age groups to
estimate age-to-age specific transmission rates consistent with the
current US distribution of pertussis cases. The calibration, using a
maximum likelihood estimation approach, was conducted using
Microsoft Solver to find the best fit to US age-specific pertussis
incidence rates.
Tdap Vaccination Dynamic Model
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costs associated with each case of pertussis (Figure 2). Incidence
rates derived for each vaccination strategy from the transmission
model were applied to the 2010 US population and used as inputs
for the economic assessment. The economic analysis was age-
stratified into 5 groups: infants (aged ,1 year), children (1–9
years), adolescents (10–19 years), and adults (stratified as 20–64
and $65 years). Each pertussis case may be mild, moderate, or
severe. Only a portion of mild cases will be treated and incur
medical and non-medical costs (in addition to the loss of quality-of-
life). Severe cases may lead to encephalopathy and/or death; other
sequelae of pertussis such as pneumonia were not explicitly
modeled, but were accounted for in cost and utility estimates for
severe cases. Direct medical and non-medical costs and quality-
adjusted life-years (QALYs) lost due to pertussis were assigned to
each case based on severity.
Epidemiologic and vaccine efficacy inputs
DTaP vaccine efficacy was derived from prescribing informa-
tion for the GSK DTaP vaccine (InfanrixH, GlaxoSmithKline)
(Table 1) [19]. In the base case, Tdap vaccine was estimated to be
89% effective based on pertussis immunogenicity licensing criteria
in a vaccine efficacy trial of DTaP [20]. An alternative scenario
analysis was conducted assuming 77% efficacy based on the lower
limit of the 95% confidence interval in the DTaP vaccine efficacy
trial [20]. Waning of vaccine efficacy is assumed to follow an
exponential distribution with a mean duration of protection of 8
years (median 5.5 years) [14]. Sensitivity analyses were conducted
with alternative mean duration of protection estimates of 6 and 2
years. For simplicity, DTaP infant vaccine protection was assumed
to take effect at 7 months of age.
In the model, individuals are protected from pertussis either by
maternal antibodies (for infants), acquisition of disease, or
vaccination; the model assumes no difference between duration
of protection from vaccination and from infection. The proportion
of infants with maternal antibodies and the duration of protection
from each source were estimated from published and publicly
available studies [14,21–23] and clinical opinion. Duration of
infectiousness was assumed to differ by type of infection (primary
versus recidive) [14,16].
DTaP and Tdap vaccine coverage for those aged ,65 years
were estimated from 2010 National Health Interview Survey
(NHIS) data. [24–26]. For the intervention strategy, we assumed
that 10% of the total population of adults aged 65 years receives
Tdap. This is consistent with the assumption that 10% of the
population aged 65 years is eligible for the decennial Td booster,
and 100% of this group receives Tdap; in sensitivity analyses, we
halved this number. Because the analysis is performed at
equilibrium, 10% of individuals in each age stratum .65 years
are assumed to have been vaccinated at age 65, and retain residual
vaccine protection consistent with waning assumptions.
Incidence rates used for model calibration were based on 2010
California Department of Public Health surveillance data and
2009 Centers for Disease Control and Prevention (CDC) data
[8,27]. Incidence rates for infants and children ,18 were
estimated directly from the California data, using the reported
incidence among infants ,6 months (435 cases/100,000) as the
estimated incidence for all infants. For adults 65 years and older,
we inflated the CDC 2009 data, assuming 1% reporting,
consistent with CDC assumptions [28]. To estimate the incidence
for adults aged 18–64, the adjusted incidence for adults aged $65
years was multiplied by the ratio of California incidence among
adults 18–64 to California incidence among adults aged $65
years. Incidence rates were varied in sensitivity analyses, by
adjusting the incidence of disease among adults aged $65 years
from 25–200 cases per 100,000 in fixed increments, while the
incidence among younger adults was increased or decreased as a
fixed proportion of the $65 incidence and pediatric incidence was
Figure 1. Transmission Model.
doi:10.1371/journal.pone.0072723.g001
Tdap Vaccination Dynamic Model
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California incidence among infants aged ,6 months and children
6 months to 6 years of age (61.8 cases/100,000), for a mean of 248
cases/100,000 [8].
Age-to-age specific contact rates used in the transmission model
were based on mean daily time of exposure between individuals by
age group in the US from 1987–2003 [29]; the contact matrix
indicates that most contacts occur between persons of similar age
and between parents and children. An alternative contact matrix
with European estimates of number of daily contacts was used in
sensitivity analyses [30].
Economic inputs
Cases generated by the model were stratified by age: ,1, 1–9,
10–19, 20–64, and $65 years old. We further classified each case
as severe (requiring hospitalization), moderate (non-hospitalized
cases with symptoms of paroxysmal cough), or mild (no
paroxysmal cough) as shown in Figure 2. The age-specific
proportions of mild, moderate, and severe cases were estimated
based on published sources [31,32].
The cost of treating a mild case was estimated as the cost of
antibiotics [33,34] and a physician visit [35]. The cost of treating a
moderate case was based on a prospective study of pertussis
morbidity among families in a community setting; costs include
physician visits, emergency room (ER) visits, laboratory, and
pharmacy costs [36]. The cost of treating a severe case of pertussis
was based on total hospitalization cost for pertussis hospitalizations
[37].
Patients with severe pertussis are at risk of encephalopathy or
death. The probabilities of encephalopathy or death among severe
cases were based on 1997–2000 data for reported hospitalized
cases [29]. We used the probability of encephalopathy to estimate
loss of quality-of-life associated with long-term disability in
addition to the loss of quality-adjusted life-years due to death.
We estimated that 33% of encephalitis cases would result in
permanent sequelae, characteristic of encephalopathy [29].
Because the acute cost of encephalopathy was assumed to be
included in the hospitalization cost, it was not estimated
separately; long-term costs of encephalopathy were not consid-
ered. A scenario assuming no cases of encephalopathy was also
included as a sensitivity analysis. Due to limited data on treatment
of mild pertussis, we assumed that the proportion of mild pertussis
cases seeking treatment is the same as the proportion of influenza
patients receiving outpatient care [38].
Costs were derived from published and publicly available
sources and were converted to 2010 U.S. dollars, as necessary,
using the medical component of the Consumer Price Index [39].
Vaccine price was obtained from the CDC vaccine price list [40]
and the total vaccination cost includes cost of vaccine-related
adverse events [16]. For sensitivity analyses, the lower public
sector vaccine cost estimated from the CDC vaccine price list was
used. We calculated the annual cost of the vaccination program by
multiplying the unit vaccine cost by 10% of the number of US
residents aged 65 years.
Direct non-medical costs include lost productivity from hospi-
talization due to time missed from work for hospitalized adults and
Figure 2. Economic model.
doi:10.1371/journal.pone.0072723.g002
Table 1. Parameters in the Transmission Model.
Parameter
Base-case Value [values




Proportion born with maternal antibodies 26%
Mean duration of protection due to maternal
antibodies
3 months
Mean duration of protection due to
vaccination or infection:
8 years [6,10]




DTaP, doses 1–4, at 1 year 95.0%
DTaP, dose 5, at 5 years 84.4%
Tdap, at 11 years 68.7%
Tdap, at 18–64 years, annual among
unboosted
1.7%
Tdap, at 65 years 10.0% [5.0%]
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and hospitalization in infants, children, and adolescents. Age-
specific work loss due to hospitalization was applied to severe cases
only. We estimated lost productivity based on published estimates
of hospital length of stay combined with estimates of the age
group-specific employment rates [14,16,41,42]. Lost productivity
for caregivers of children was calculated based on the wage rate for
adults aged 20–64 years. We assumed no caregiver time loss for
adult cases (including adults aged 65 years and older).
Utility values, preference-based measures of quality-of-life
ranging from 0 to 1 used to calculate QALYs, were obtained
from published literature [14,41,43]. Disutilities for mild, moder-
ate, and severe pertussis and encephalopathy were used to estimate
the quality of life loss associated with pertussis. Disutilities
associated with acute disease symptoms were assigned to pertussis
cases for lengths of time that differed by severity and age, based on
duration of mild, moderate, and severe symptoms. Total duration
of illness, obtained from published literature [14], was assumed to
be the same for severe, moderate, and mild disease (Table 2). A
mild case was assumed to incur the mild symptom disutility for the
full length of illness. Moderate adolescent/adult cases receive two
weeks of moderate symptom disutility followed by mild symptoms
disutility for the remaining days of illness. A severe adolescent/
adult case incurs two weeks of severe symptom disutility followed
by mild symptoms disutility for the remaining days of illness.
Similarly, infants are assumed to incur 4 weeks of moderate or
Table 2. Parameters in the Economic Model.
Parameter Age Group (years)/Base-case Value [values used in sensitivity analyses]
,1 1–9 10–19 20–64 $65
Population 310,751,161
Population distribution 1.39% 12.27% 13.24% 60.03% 13.06%
Clinical
Proportion of Severe, Moderate,
and Mild Cases*
% mild 82.1% 21.2% 24.3% 11.0% 14.0%
% moderate 7.4% 73.3% 73.6% 86.0% 74.0%
% severe 10.5% 5.5% 2.1% 3.0% 12.0%
% with encephalopathy (permanent
sequelae) among
severe cases
0.32% 0.71% 2.38% 1.43% 1.43%
% dying among severe cases 1.18% 0.71% 0.00% 0.86% 0.86%
% mild cases that receive medical care 47.1% 40.5% 35.2% 37.2% 70.7%
Duration of symptoms 80 days [56] 56 days 74 days [56] 87 days [56] 87 days [56]
Costs
Vaccine Cost NA NA NA NA $18.10 [$16.16, $17.84]
Cost of Treating Pertussis, by Severity:
Mild $82.80 $93.00 $101.66 $99.22 $99.22
Moderate $607.21 $322.83 $268.83 $204.72 $203.13
Severe $13,029.47 $6,431.77 $7,066.87 $7,221.97 $7,221.97
Days of work lost due to acute illness
incurred by caregiver (all treated cases)
2.1 2.1 0.8 - -
Days of work lost due to hospitalization
(severe only)
By caregiver 2.1 1.3 1.1 - -
By self - - 0.3 2.4 0.6
Value of lost productivity per day NA
{ NA
{ $52.38 $157.45 $114.30
Disutility
Pertussis symptoms:
Mild 0.15 [0.14,0.12] 0.18 [0.17,0.15] 0.14 [0.13,0.11] 0.1 [0.09,0.08] 0.1 [0.09,0.08]
Moderate 0.15 [0.14,0.12] 0.26 [0.23,0.21] 0.21 [0.18,0.16] 0.15 [0.14,0.12] 0.15 [0.14,0.12]
Severe 0.42 [0.38,0.34] 0.37 [0.33,0.30] 0.3 [0.27,0.24] 0.19 [0.17,0.15] 0.19 [0.17,0.15]
Encephalopathy 0.20 [0.18,0.16] 0.20 [0.18,0.16] 0.20 [0.18,0.16] 0.20 [0.18,0.16] 0.20 [0.18,0.16]
*The number of cases that are mild among children less than 10 years old was based on the proportion of unreported cases, while those in individuals 10 years and
older was based on the percentage of reported cases without paroxysmal cough [10,31]. The proportion of cases that are severe was based on hospitalization rates
[10,32]. In children less than 10 years old, hospitalization rates were only applied to reported cases. The proportion of cases that are moderate was assumed to be those
not classified as severe or mild.
{Lost productivity per day for children ,10 years old was assumed to be incurred by adults 20–64 years old.
doi:10.1371/journal.pone.0072723.t002
Tdap Vaccination Dynamic Model
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e72723severe symptoms disutility followed by mild, and children incur 3
weeks of moderate or severe symptoms disutility followed by mild.
Sensitivity analyses were conducted with reduced duration of
illness and reduced duration of the most severe symptoms.
In addition to disutility of acute illness, patients with enceph-
alopathy are assumed to incur the disutility for encephalopathy for
the remainder of their lifetime. Loss of QALYs due to death was
based on age-specific US population norms [44]. Total QALYs
lost due to death or encephalopathy were calculated as the
discounted present values of the lost utility streams over the
remaining expected lifetime, based on age-specific life expectancy
[45] at the time of the event. In sensitivity analyses, we explored
how results change if reductions in utility are 20% smaller than the
base-case value.
Analyses
Outcomes were assessed for the entire US population, including
children and adults outside the target $65 age group, to capture
the indirect benefits of vaccination in the unvaccinated population.
The epidemiologic model uses a time step of 1/1200 year, or
approximately 7 hours, to simulate continuous movement between
compartments. The transmission model was calibrated and run
assuming 1000 individuals in each one-year age group to calculate
disease rates. The model estimates age-specific incidence rates of
primary and recidive infection; these rates are then projected over
the US population to estimate pertussis incidence under both the
baseline and intervention strategies. When linked with the
epidemiologic model, the economic model projects costs and
QALYs associated with vaccination and pertussis. Cost measures
include direct medical costs, (costs of vaccination and costs of
treating pertussis cases), and direct non-medical costs (lost
productivity from hospitalization and caregiver time) for the
societal perspective. The payer perspective excludes direct non-
medical costs. The model estimates cases avoided stratified by
severity, deaths avoided, encephalopathy avoided, and, where
applicable, incremental cost-effectiveness ratios (ICER) in terms of
incremental cost/QALY gained. Costs and utility reductions
associated with acute illness are assumed to occur within the one-
year time horizon and therefore are not discounted. Lifetime
QALYs lost due to death and encephalopathy are discounted at
3% per year back to the base year in which the event occurs,
consistent with US recommendations [46].
Sensitivity analyses
To assess the sensitivity of the model results to manipulation of
influential parameters, a series of deterministic sensitivity analyses
were conducted, by varying incidence, duration of protection,
vaccine efficacy, vaccine coverage, vaccine cost, as well as direct
medical and non-medical costs using a previously published cost-
effectiveness study as an alternative secondary source [16].
Additional scenario analyses were conducted in which we used a
European contact matrix [31], assumed 0% encephalopathy,
decreased utility losses, and reduced the duration of the most
severe pertussis symptoms. In addition, we replicated assumptions
from a previously-published economic analysis [14], assuming the
same structure and transmission parameter estimates, to explore
the impact of including asymptomatic infections in the disease
model.
Results
Under both the baseline and intervention strategies, the model
predicts that the one-year pertussis incidence will be greatest
among infants, followed by adults aged 20–64 years, adults aged
$65 years, children, and adolescents (results not shown). Incidence
rates of pertussis infection among infants, children, adolescents,
and adults aged 20–64 years are predicted to decrease by
approximately 28–29% with the intervention strategy, whereas
in adults aged $65 years, the yearly incidence rate is predicted to
decrease by 34% (results not shown). The numbers of cases
avoided by the intervention strategy, by age group, is reported in
Table 3. The greatest number of cases avoided (.66,000) is
observed among adults aged 20–64 years, although when adjusted
for the size of the affected population, the impact is greatest among
infants. For the US population of 311 million, the intervention
strategy is expected to prevent 4,188 severe cases, 72,506
moderate cases, and 20,357 mild cases of pertussis per year at
steady state.
Introduction of the intervention strategy is expected to lead to
yearly direct medical cost savings of approximately $49.5 million.
From the societal perspective, cost savings related to acute
pertussis infection and outcomes increase to $52.4 million per
year (Table 4, top panel). The additional total yearly cost of
vaccinating all individuals aged 65 years under the intervention
versus baseline strategy is estimated to be $4.7 million (Table 4,
middle panel). The net cost savings including the cost of the
vaccination program are $44.8 million from the payer perspective,
and $47.7 million from the societal perspective (Table 4, bottom
panel). In the base case, the intervention strategy dominates the
Table 3. Cases Avoided with Intervention Strategy, by Age Group, Case Severity, and Treatment.
Age Group (years)
Case Type ,1 1–9 10–19 20–64 $65 All ages
Severe cases 525 109 140 1,987 1,427 4,188
Deaths 6.2 0.8 0.0 17.0 12.2 36.2
Encephalopathy 1.7 0.8 3.3 28.1 20.2 54.2
Moderate Cases 372 1,454 4,921 56,961 8,798 72,506
Mild Cases 4,458 5,323 1,626 7,286 1,664 20,357
Treated 2,100 2,159 573 2,707 1,176 8,715
Untreated 2357 3165 1053 4579 488 11642
Total Cases 5,355 6,886 6,687 66,234 11,889 97,051
doi:10.1371/journal.pone.0072723.t003
Tdap Vaccination Dynamic Model
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.3,000 QALYs) than the baseline strategy (Table 5).
Sensitivity analyses
Increasing the incidence of pertussis from the base case of 86.6
cases per 10,000 in those aged $65 years to 200 cases per 100,000
results in a $6.8 million increase in cost savings and nearly 400
more incremental QALYs gained (societal perspective) for the
intervention strategy (Figure 3). Reducing incidence has the
opposite effect of reducing cost savings and QALYs gained; the
Tdap vaccination program nevertheless remains dominant even at
incidence as low as 25 cases per 100,000 in those aged $65 years.
As expected, decreasing vaccine efficacy and coverage and
accelerating waning of vaccine protection results in lower cost
savings and fewer QALYs gained. Likewise, alternative assump-
tions that reduce the impact of disease, including removing
encephalopathy from the model, decreasing utility losses associ-
ated with disease, decreasing the duration of illness and decreasing
the duration of the most severe symptoms, all result in fewer cost
savings and/or QALYs gained. Assuming lower vaccine costs
using public pricing increases cost savings by $500,000 per year
while using the alternative source for costs increases cost savings by
$27 million. Including asymptomatic infection in the model results
in approximately 430 fewer QALYs gained and decreases cost
savings by .$6 million because the natural protection provided by
asymptomatic infection reduces the potential benefit of the
vaccine. Recalibrating and rerunning the model using the
alternative European contact matrix results in .100,000 more
cases prevented and almost $60 million more in cost savings; this
appears due to greater contact between those aged $65 years and
both infants and adolescents in Europe. Under all scenarios
examined, the intervention strategy remains dominant (less costly
and more effective than the baseline strategy) from both the payer
and societal perspectives.
Discussion
We constructed a population-level disease-transmission model
to assess the cost effectiveness of replacing the decennial Td
booster with Tdap in adults aged 65 compared to baseline practice
prior to 2010 of no Tdap vaccination in this age group. Model
results indicate that administering Tdap booster vaccination to
10% of eligible adults at the age of 65 years would prevent 97,000
cases of pertussis each year (.5,300 in infants), including 4,200
severe cases (.500 in infants). Vaccinating eligible adults aged 65
years is cost-saving, providing annual net societal cost savings of
$44.7 million and $47.7 million, from the payer and societal
perspectives, respectively. In the base case as well as all sensitivity
analyses, the strategy of adding Tdap vaccination in the adults
aged 65 years to the baseline strategy is dominant compared to the
baseline strategy, as it is both less costly and more effective than
the baseline strategy.
Although no other published models have specifically examined
the cost-effectiveness of vaccinating the US population aged $65
years with Tdap, our findings are generally consistent with a
recent analysis by Coudeville and colleagues in which they
evaluated the cost-effectiveness of adult vaccination in the
presence of infant and adolescent vaccination using a dynamic
transmission model. They found strategies of adding one-time
adult boosting at age 40 with cocooning, and repeated decennial
adult vaccination, both to be dominant versus the baseline strategy
of infant plus adolescent vaccination in terms of life-years saved
[15]. Although Coudeville found the optimal age at boosting to be
40 years, given the low coverage in this age group, the strategy we
examine of vaccinating adults aged $65 years may be an effective
approach to increasing overall adult coverage.
Our finding that Tdap vaccination in adults aged 65 years is
cost-saving can be compared to other studies of vaccination in this
population. For example, a strategy of universal influenza
vaccination including vaccination of those aged $65 years was
similarly found to be cost-saving [47]. In contrast, a recent analysis
of replacement of the 23-valent polysaccharide pneumococcal
vaccine with the 13-valent conjugate vaccine in routine vaccina-
tion at ages $65 years found this switch to be more costly, but
cost-effective at $28 900 per QALY gained [48]. Similarly,
vaccinating adults aged .60 years for herpes zoster was estimated
to cost ,$50,000 per QALY gained [49]. These studies did not
consider indirect effects in the unvaccinated populations, and
results may have been more favorable had these effects been taken
into account.
Table 4. Incremental Costs of Intervention Strategy.
Age Group (years)
Cost Item ,1 1–9 10–19 20–64 $65 All ages
Costs (Savings)
Mild treated ($173,902) ($200,740) ($58,250) ($268,594) ($116,697) ($818,183)
Moderate ($226,103) ($469,358) ($1,322,867) ($11,660,750) ($1,787,022) ($15,466,101)
Severe ($6,839,132) ($703,840) ($992,437) ($14,350,102) ($10,303,145) ($33,188,657)
Direct Medical ($7,239,138) ($1,373,939) ($2,373,554) ($26,279,446) ($12,206,864) ($49,472,941)
Lost productivity ($1,183,730) ($806,503) ($121,473) ($749,418) ($89,816) ($2,950,939)
Direct Medical and Non-medical ($8,422,867) ($2,180,441) ($2,495,027) ($27,028,864) ($12,296,680) ($52,423,880)
Vaccination Costs
Incremental vaccination costs $0 $0 $0 $0 $4,691,839 $4,691,839
Net Costs (Savings)
Excluding productivity loss ($1,580,476) ($1,339,145) ($336,222) ($55,113,000) ($7,515,026) ($44,781,102)
Including productivity loss ($8,422,867) ($2,180,441) ($2,495,027) ($27,028,864) ($7,604,842) ($47,732,041)
doi:10.1371/journal.pone.0072723.t004
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assumptions, and limitations of the model should be considered
when interpreting results. The transmission model structure is a
simplified representation of disease transmission and outcomes of
pertussis. The possible transitions between health states in the
model are based on our current understanding of pertussis
epidemiology, but may be subject to revision as new information
becomes available. In addition, although we accounted for
differences in treatment and outcomes in the model using
stratification by age and disease severity, we recognize that the
diversity of the US population and the complexity of the health-
care delivery system may not be well represented by the relatively
simple structure of this model. Furthermore, this model is not
structured to capture family or household dynamics that would
allow for evaluation of cocooning related to vaccination of those
aged $65 years. To evaluate this effect, the model would have to
account for grandparents’ higher likelihood of both interacting
with grandchildren and of vaccination, whereas our model treats
those aged $65 years as a homogeneous population. In addition,
because younger adults interact with both infants and grandpar-
ents, if we had assumed vaccination uptake in this age group to be
weighted toward parents and caregivers this also may have
affected model results. Because cocooning targets vaccination to
those most likely to transmit disease to infants, a model including
cocooning likely would have predicted more infant disease
prevented with the $65 Tdap vaccination program.
We also note that our model structure does not take into
account other epidemiologic phenomena related to pertussis
incidence, including the possible loss of boosting of pertussis
immunity with lower incidence of disease, or the possible
replacement of the vaccine type strains by more virulent strains
of pertussis [50]. Modeling these phenomena would require a
more complex model than that described in this report, as well as
greater understanding of the disease dynamics of pertussis.
Table 5. Base-case Results.
Societal perspective (including lost productivity)
Comparator Total Costs QALYs lost Incremental Cost Incremental QALYs ICER
Baseline strategy $238,884,106 11,614 – – Reference
Intervention strategy $191,152,065 8,227 2$47,732,041 3,387 Dominant
Payer perspective (excluding lost productivity)
Baseline strategy $228,571,260 11,614 – – Reference
Intervention strategy $183,790,158 8,227 2$44,781,102 3,387 Dominant
doi:10.1371/journal.pone.0072723.t005
Figure 3. Sensitivity and scenario analyses varying selected parameters.
doi:10.1371/journal.pone.0072723.g003
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intervention vaccination program versus the baseline vaccination
program assuming both are at equilibrium; however, recent
pertussis incidence data have shown a pattern of decreased
incidence following the 2005 adult and adolescent vaccination
recommendation, followed by an apparent increasing trend in
incidence thereafter. Because the reason for this recent pattern in
incidence is unclear and may represent changes in reporting rather
than in the true incidence, we chose to assume that incidence is
neither increasing nor decreasing for our analyses.
A further potential limitation of the steady-state analysis is that it
does not take into account the difference in timing between
vaccine costs and benefits accruing from the program. The
current-year benefits of the pertussis vaccination program are due
not only to the protection provided to individuals vaccinated in the
current year but also to those vaccinated in prior years whose
protection is waning. At the same time, the one-year model does
not capture the full benefits of the current year’s vaccination
program, as many of these benefits will be realized in the future,
beyond the model time horizon. At steady state, we may assume
that any benefits of past vaccination being counted in the current
year are perfectly offset by the uncounted future benefits of the
current year’s vaccination program. However, this assumption
disregards the vaccine costs incurred at the start of the vaccination
program before equilibrium was achieved, as the decrease in cases
with the fully-implemented program at steady state is due, in part,
to changes in disease epidemiology that likely took several years of
vaccination to achieve. To investigate the change in disease
incidence over time, we ran the model to steady state and found
that the yearly incidence indeed declined slowly, with the initial
post-vaccination years experiencing only modest declines in
incidence, and the herd effect building over time.
In addition to the structural limitations in the model design, we
note that data used to estimate model inputs were derived and
synthesized from a variety of sources; this process is subject to bias
and different assumptions may have yielded different results. In
particular, recent outbreaks and supporting epidemiologic data
have called into question the effectiveness and durability of
protection from vaccination with acellular pertussis vaccine [7,9].
Published estimates from California, suggest that the acellular
pertussis vaccine may wane to 47% of its original efficacy after 5
years (i.e., from 90% to 42% efficacy) [9]. Assuming a constant
waning rate, this suggests a mean time to waning of 6.6 years;
sensitivity analyses demonstrate that even assuming this shorter
period of effectiveness, the vaccine would remain cost-saving in
our model. We further found that even under very unfavorable
assumptions in which the protection afforded by pertussis infection
is assumed to be 8 years and that provided by vaccination 2 years,
the 65+ vaccination program is expected to save $2.7 million.
Because of underreporting of pertussis to US surveillance
systems, the true incidence of pertussis is unknown and was
estimated by combining data sources and inflating CDC estimates.
The data and assumptions used to derive these estimates could not
be externally verified and may have provided over- or under-
estimates of the true incidence across age groups. Moreover, by
calibrating the model to 2010 incidence data in the transmission
model, collected only 5 years after the Tdap vaccination was
expanded to adolescents and adults, we are potentially overesti-
mating pertussis incidence at steady state. However, even in
sensitivity analyses in which we scaled the incidence estimates from
the basecase of 86 per 100,000 among those $65 to 50 and 25 per
100,000, Tdap remained cost saving with estimated savings of
$29.7 and $10.6, million respectively, from the societal perspective.
We further note that our assumption that 10% of those aged 65
would be vaccinated per year may be optimistic, given current US
vaccination rates for TD (54.4% report receiving in the last ten
years) and pneumococcal vaccines (62.3% report receiving ever) in
the $65 age group [51]. However, sensitivity analyses showed that
even if only 5% of those aged 65 are vaccinated per year, the
vaccine remains cost saving, and provides substantial benefits.
Sensitivity and scenario analyses, in which we varied inputs for
incidence, contact matrix, age of DTaP protection, waning rates,
vaccine efficacy, vaccine coverage, vaccine cost, direct medical
and indirect costs, and discounting, show the intervention
vaccination program remains cost saving under all scenarios
examined, with savings ranging from approximately $100,000 to
$10 million compared to the baseline vaccination strategy.
In conclusion, our study found the program of replacing the
decennial Td booster with Tdap among US residents aged 65
years is projected to prevent 97,000 cases of pertussis per year, and
is cost-saving from societal and payer perspectives.
InfanrixH is a trademark of the GlaxoSmithKline group of
companies.
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